淋巴瘤

预约门诊

Lymphoma survival rates

Survival rates for lymphoma are different for each type of lymphoma. They also depend on your overall health, the stage of your cancer and which treatments you are getting. To understand lymphoma survival rates, experts study many people with lymphoma to see how many are living five years after their diagnosis.

For stage 1 Hodgkin lymphoma, the chance of surviving at least five years is 92%. As the cancer spreads, the chances get lower. For stage 4 Hodgkin lymphoma, the chance of surviving at least five years is about 82%.

For stage 1 non-Hodgkin lymphoma, the chance of surviving at least five years is 87%. As the cancer spreads, the chances get lower. For stage 4 non-Hodgkin lymphoma, the chance of surviving at least five years is about 63%.

Keep in mind that survival statistics take five years to collect. The most recent survival rates include people who had lymphoma treatment more than five years ago. These people may not have had access to the latest treatments. Over the last few decades, lymphoma death rates have been falling and survival rates have been increasing.

申请预约
诊断与治疗
Dec. 20, 2024

Living with 淋巴瘤?

Connect with others like you for support and answers to your questions in the CAR-T Cell Therapy support group on Mayo Clinic Connect, a patient community.

CAR-T Cell Therapy Discussions

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

776 Replies Tue, Sep 16, 2025

Bob, Alumni Mentor
CAR-T cell Therapy: Joint and muscle pain

50 Replies Fri, Sep 05, 2025

Heather McFarland
A Summary of My Multiple Myeloma

47 Replies Fri, Aug 29, 2025

See more discussions
  1. Lymphoma – Non-Hodgkin. Cancer.Net. https:www.cancer.net/cancer-types/41246/view-all. Accessed Dec. 18, 2023.
  2. Lymphoma – Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma. Accessed Dec. 18, 2023.
  3. What causes non-Hodgkin lymphoma? American Cancer Society. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/causes-risks-prevention/what-causes.html. Accessed Dec. 21, 2023.
  4. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Dec. 21, 2023.
  5. Freedman A, et al. Clinical presentation and initial evaluation of non-Hodgkin lymphoma. https://www.uptodate.com/contents/search. Accessed Jan. 30, 2024.
  6. Lymphoma – Non-Hodgkin: Diagnosis. https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/diagnosis. Accessed Dec. 22, 2023.
  7. Non-Hodgkin lymphoma treatment (PDQ) – Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Jan. 1, 2024.
  8. Brondfield S, et al. Developing a community for patients with cancer through longer-term art therapy. Oncology Practice. 2020; doi:10.1200/OP.20.00419.
  9. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Jan. 3, 2024.
  10. Coping with cancer. Cancer.Net. https://www.cancer.net/coping-with-cancer. Accessed Jan. 4, 2024.
  11. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-Cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  12. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  13. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed April 14, 2024.
  14. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed April 14, 2024.

淋巴瘤

CON-20304579